LIBTAYO 350 mg concentrate for solution for infusion. clinical trials
13 indexed studies · 0 currently recruiting
- AuthorisedTherapeutic exploratory (Phase II)
Mechanisms of Resistance to anti-PD-1 Therapy in cutaneous Squamous Cell Carcinomas: Impact of Tumor Cell Plasticity on Promoting Myeloid Suppressor Cell Infiltration. A phase II single arm, unicenter study of cemiplimab in patients with locally advanced cSCCs.
This study is looking at how a medicine called cemiplimab (Libtayo) works in people with advanced skin cancer (cutaneous squamous cell carcinoma). Researchers want to understand why some people respond well and others don't, by studying blood and tumour samples.
For: Cutaneous squamous cell carcinoma (ccSCC)Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II to IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC)
This study is testing a new medicine, cemiplimab (also known as Libtayo), for a type of skin cancer called cutaneous squamous cell carcinoma. Doctors want to see if giving this medicine before surgery can completely clear the cancer cells at the original site.
For: Stage II to IV cutaneous squamous cell carcinomaGermany - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
An Open Label, Phase 1/2 Study of HST-1011 Given as Monotherapy and in Combination with an Anti-PD1 Antibody in Patients with Advanced Solid Tumors
This study is testing a new medicine called HST-1011, by itself and with another medicine called Libtayo, for people with advanced cancers. Researchers want to see if these treatments are safe, how they work in the body, and if they help shrink tumors.
For: Advanced Solid TumorsSpain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Multicenter, Open-label, Phase 2 study of Intratumoral Vidutolimod (CMP-001) in Combination with Intravenous Cemiplimab in Subjects with Selected Types of Advanced or Metastatic Cancer
This study is testing a new combination of treatments for some advanced cancers. It involves two drugs, Vidutolimod and Cemiplimab, to see how well they shrink tumours. It's a Phase II study, meaning we're looking at how safe and effective this new approach might be.
For: Advanced or Metastatic Cancer Merkel Cell Carcinoma (MCC) Cutaneous Squamous Cell Carcinoma (CSCC) Basal Cell Carcinoma (BCC) Triple Negative Breast Cancer (TNBC) Non-Small Cell Lung Cancer (NSCLC)France - Ongoing, recruitingTherapeutic exploratory (Phase II)
Open-label, randomized Phase II trial with BNT111 and cemiplimab in combination or as single agents in patients with anti-PD 1/PD-L1-refractory/relapsed, unresectable Stage III or IV melanoma
This study is looking at new ways to treat advanced melanoma that hasn't responded to previous treatments. It compares a new drug, BNT111, alone and in combination with an existing drug, Libtayo, to see if they can shrink tumours or stop them from growing.
For: Melanoma (Stage III and IV)Spain · Germany · Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Global, Randomized, Phase 3, Open-Label Study of REGN2810 (Anti-PD-1 Antibody) versus Platinum-Based Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic PD-L1 + Non-Small Cell Lung Cancer
This study looks at a new drug (REGN2810) compared to standard chemotherapy for advanced non-small cell lung cancer. It aims to see if the new drug helps people live longer and stops cancer from growing, especially for those whose cancer has a specific protein called PD-L1.
For: Non-small Cell Lung CancerCzechia · Poland · Greece - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Two-Part Randomized, Phase 3 Study of Combinations of Cemiplimab (Anti- PD-1 Antibody) and Platinum-based Doublet Chemotherapy in First-line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer
This study is testing new combinations of anti-cancer medicines for people with advanced non-small cell lung cancer. It aims to see if these new approaches can help people live longer and improve their quality of life, compared to standard treatments.
For: Non-small Cell Lung CancerFrance · Poland · Ireland - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A PHASE 1/2 STUDY OF ONCOBAX®-AK ADMINISTERED IN COMBINATION WITH IMMUNOTHERAPY TO PATIENTS WITH ADVANCED SOLID TUMORS
This study is testing a new treatment called Oncobax®-AK, given alongside established immunotherapy drugs, for people with advanced lung or kidney cancer. It's looking for the safest dose and early signs of how well it works. This is an early-stage trial, focusing on safety.
For: Non-Small Cell Lung Cancer (NSCLC) · Renal Cell Carcinoma (RCC)Belgium · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma [CERPASS]
This study is looking at a new treatment for advanced skin cancer (cutaneous squamous cell carcinoma). It's testing a drug called cemiplimab, either alone or with another treatment called Vusolimogene oderparepvec, to see how well they shrink tumours and if they are safe.
For: Cutaneous Squamous Cell CarcinomaSpain · Greece · Germany - AuthorisedTherapeutic exploratory (Phase II)
Extended Follow-up of Patients with Melanoma Treated with Fianlimab Plus Cemiplimab in Expansion Cohorts from R3767-ONC-1613
This study is looking at how well two medicines, fianlimab and cemiplimab, work together to treat a type of skin cancer called melanoma. Researchers are checking how long people live after having this combination treatment and if the cancer comes back or gets worse.
For: MelanomaIreland - AuthorisedHuman Pharmacology (Phase I)- First administration to humans
A phase 1b study of an autologous dendritic cell immunotherapy in combination with anti-programmed death-1 treatment in patients with metastatic non-small-cell lung cancer (DARE-LUNG)
This study is looking at a new way to treat an advanced form of lung cancer. It combines a special vaccine made from your own cells with an existing cancer medicine to see if it helps reduce side effects and works better.
For: metastatic non-small-cell lung cancerBelgium - AuthorisedTherapeutic exploratory (Phase II)
Phase II study of Cemiplimab before and after standard chemoradiotherapy for patients with locally advanced cervical carcinoma. CADILLACC TRIAL
This study is testing a new way to treat locally advanced cervical cancer. It combines standard chemotherapy and radiation with a new drug called Libtayo before and after those treatments, to see if it helps reduce the cancer.
For: locally advanced cervical carcinomaItaly - AuthorisedTherapeutic exploratory (Phase II)
Hyperprogression upon cemiplimab alone or with chemotherapy in PD-L1 ≥ 50% NSCLC: a biomarker guided phase 2 trial – HYPERBOLIC study
This study looks at a new cancer drug, cemiplimab (Libtayo), sometimes with chemotherapy, for advanced lung cancer. It checks if the cancer grows very quickly in some patients and how safe and effective the treatments are.
For: non-small cell lung cancer (NSCLC)Italy